Portugal

First cancer messenger RNA vaccine reduces the risk of relapse by 42%

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 24/10/2026, 14:50:25 UTC.

Briefings

A first clinical trial demonstrates that combining a personalized mRNA vaccine with immunotherapy reduces melanoma recurrence risk by 42%. This represents the initial successful application of this technology in cancer treatment.

Key points

• A personalized mRNA vaccine combined with immunotherapy reduced melanoma recurrence risk by 42% in a clinical trial.
• This is the first time the technology has been successfully applied to cancer treatment.

Context

The evidence describes a clinical trial where a personalized mRNA vaccine was paired with immunotherapy to treat melanoma. This marks the initial successful application of the technology in cancer treatment.

Limitations

The evidence is limited to a single clinical trial. No additional background context is supplied, and the study's findings remain preliminary as this is the first successful application of the technology in cancer treatment.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 24/10/2026, 16:14:57 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidanhrudunkqk4nlaezg7gwwsvihccx7eykg4axy2gremhg4qpfqe